Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Papaioannou (Chaidari, Athens(Athens), Greece), M. Mplizou (Chaidari,(Athens), Greece), K. Porpodis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), E. Zervas (Athens, Greece), K. Samitas (Athens, Greece), M. Markatos (Chania, Greece), S. Papiris (Chaidari, Athens(Athens), Greece), M. Gaga (Athens, Greece), D. Papakosta (Thessaloniki, Greece), S. Loukides (Chaidari, Athens(Athens), Greece). Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study. 2226

Member's Comments

No comment yet.

Related content which might interest you: Clinical benefits and safety of long term treatment with Montelukast in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 One year of mepolizumab in severe asthma in Italy: efficacy and safety Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 A long term randomized clinical study of 300 asthmatics. An internet based asthma monitoring tool improves quality of life significantly Source: Eur Respir J 2004; 24: Suppl. 48, 261s Year: 2004 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study Source: Eur Respir J, 54 (6) 1900901; 10.1183/13993003.00901-2019 Year: 2019 Can Internet-based management improve asthma control? A long term randomised clinical study of 300 asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 44s Year: 2005 Longterm safety study of FlutiFormÔ HFA in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017